CRISPR Therapeutics, Vertex Get FDA Green Light for Sickle Cell Test

The FDA has lifted its hold on a clinical trial for a genetically engineered treatment for sickle cell disease, and CRISPR Therapeutics and Vertex Pharmaceuticals say they plan to start testing the therapy in U.S. patients by the end of the year. Enrollment is already underway for a clinical trial in Europe.